Phase I dendritic cell p53 peptide vaccine for head and neck cancer
PJ Schuler, M Harasymczuk, C Visus, A DeLeo… - Clinical Cancer …, 2014 - AACR
Background: p53 accumulation in head and neck squamous cell carcinoma (HNSCC) cells
creates a targetable tumor antigen. Adjuvant dendritic cell (DC)–based vaccination against …
creates a targetable tumor antigen. Adjuvant dendritic cell (DC)–based vaccination against …
[PDF][PDF] Phase I Dendritic Cell p53 Peptide Vaccine for Head and Neck Cancer
PJ Schuler, M Harasymczuk, C Visus, A DeLeo… - Clin Cancer …, 2014 - researchgate.net
Background: p53 accumulation in head and neck squamous cell carcinoma (HNSCC) cells
creates a targetable tumor antigen. Adjuvant dendritic cell (DC)–based vaccination against …
creates a targetable tumor antigen. Adjuvant dendritic cell (DC)–based vaccination against …
[引用][C] Phase I Dendritic Cell p53 Peptide Vaccine for Head and Neck Cancer
PJ Schuler, M Harasymczuk, C Visus, A Deleo… - 2014 - oparu.uni-ulm.de
Phase I dendritic cell p53 peptide vaccine for head and neck cancer
PJ Schuler, M Harasymczuk, C Visus… - … : an official journal …, 2014 - pubmed.ncbi.nlm.nih.gov
Background p53 accumulation in head and neck squamous cell carcinoma (HNSCC) cells
creates a targetable tumor antigen. Adjuvant dendritic cell (DC)-based vaccination against …
creates a targetable tumor antigen. Adjuvant dendritic cell (DC)-based vaccination against …
[HTML][HTML] Phase I dendritic cell p53 peptide vaccine for head and neck cancer
PJ Schuler, M Harasymczuk, C Visus… - … cancer research: an …, 2014 - ncbi.nlm.nih.gov
Background p53 accumulation in head and neck squamous cell carcinoma (HNSCC) cells
creates a targetable tumor antigen. Adjuvant dendritic cell (DC)-based vaccination against …
creates a targetable tumor antigen. Adjuvant dendritic cell (DC)-based vaccination against …
Phase I Dendritic Cell p53 Peptide Vaccine for Head and Neck Cancer
PJ Schuler, M Harasymczuk, C Visus, A DeLeo… - Clinical Cancer …, 2014 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: p> Background: p53 accumulation in head and
neck squamous cell carcinoma (HNSCC) cells creates a targetable tumor antigen. Adjuvant …
neck squamous cell carcinoma (HNSCC) cells creates a targetable tumor antigen. Adjuvant …
Phase I dendritic cell p53 peptide vaccine for head and neck cancer.
PJ Schuler, M Harasymczuk, C Visus… - … Cancer Research: an …, 2014 - europepmc.org
Phase I dendritic cell p53 peptide vaccine for head and neck cancer. - Abstract - Europe PMC
Sign in | Create an account https://orcid.org Europe PMC Menu About Tools Developers Help …
Sign in | Create an account https://orcid.org Europe PMC Menu About Tools Developers Help …
[引用][C] Phase I Dendritic Cell p53 Peptide Vaccine for Head and Neck Cancer
PJ SCHULER, M HARASYMCZUK… - Clinical cancer …, 2014 - pascal-francis.inist.fr
Phase I Dendritic Cell p53 Peptide Vaccine for Head and Neck Cancer CNRS Inist Pascal-Francis
CNRS Pascal and Francis Bibliographic Databases Simple search Advanced search Search by …
CNRS Pascal and Francis Bibliographic Databases Simple search Advanced search Search by …
[PDF][PDF] Phase I Dendritic Cell p53 Peptide Vaccine for Head and Neck Cancer
PJ Schuler, M Harasymczuk, C Visus, A DeLeo… - Clin Cancer …, 2014 - academia.edu
Background: p53 accumulation in head and neck squamous cell carcinoma (HNSCC) cells
creates a targetable tumor antigen. Adjuvant dendritic cell (DC)–based vaccination against …
creates a targetable tumor antigen. Adjuvant dendritic cell (DC)–based vaccination against …
[PDF][PDF] Phase I Dendritic Cell p53 Peptide Vaccine for Head and Neck Cancer
PJ Schuler, M Harasymczuk, C Visus, A DeLeo… - Clin Cancer …, 2014 - academia.edu
Background: p53 accumulation in head and neck squamous cell carcinoma (HNSCC) cells
creates a targetable tumor antigen. Adjuvant dendritic cell (DC)–based vaccination against …
creates a targetable tumor antigen. Adjuvant dendritic cell (DC)–based vaccination against …